22nd Sep 2020 19:36
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Secures clinical laboratory licence from California Department of Health. "KidneyIntelX may now be used to report risk assessment of progressive decline in kidney function for patients in California with early stage diabetic kidney disease. With this certification, the company is now licensed to provide KidneyIntelX testing services for patients in 49 states," Renalytix said.
Current stock price: 485.00 pence
Year-to-date change: up 33%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc